Company intelligence / Profile preview
Curamys
South Koreacuramys.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Curamys is developing a novel therapeutic platform using cell fusion technology targeting rare diseases; clinical results are preliminary and appear to be in pre-clinical or early clinical phases, with safety and early efficacy under evaluation
- Therapeutic areas
- NeurologyMetabolic DisordersRare Diseases
- Modalities
- Cell therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Curamys.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Curamys.